- Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events
- Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis
- Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
- Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis
- Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
- Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method
- Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis
- Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis
- Enlivex Announces Reprioritization Plan and Second Quarter 2023 Financial Results
- Enlivex to Present at the H.C. Wainwright 25th Annual Global Investment Conference
More ▼
Key statistics
On Thursday, Enlivex Therapeutics Ltd (ENLV:TLV) closed at 630.00, 31.25% above the 52 week low of 480.00 set on Apr 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 605.80 |
---|---|
High | 630.00 |
Low | 592.40 |
Bid | 600.00 |
Offer | 630.00 |
Previous close | 605.80 |
Average volume | 197.05k |
---|---|
Shares outstanding | 18.81m |
Free float | 15.20m |
P/E (TTM) | -- |
Market cap | 30.48m USD |
EPS (TTM) | -1.56 USD |
Data delayed at least 20 minutes, as of May 02 2024 15:27 BST.
More ▼